“Many people wonder how we’ve done in less than a year what usually takes at least 4-5 years. It is through getting rid of the dead space," said Dr Peter Marks, director of CBER, FDA
Hyderabad: During the premier keynote session of the 18th edition of BioAsia, Dr Peter Marks, director, CBER, FDA addressed the virtual audience from across the globe, with insights on Covid-19 and gaining public confidence in vaccines. He stressed on the need for overcoming vaccine hesitancy.
Dr Marks commented on FDA’s role in developing the vaccine, “We reference a standard in vaccine production. This is done to help ensure public confidence in vaccines. We need people to be willing to take the vaccine and overcome vaccine hesitancy. That is the only way we can come out of this global pandemic together.”
Speaking on acting quickly in vaccine research, trials and production, he added “Many people wonder how we’ve done in less than a year what usually takes at least 4-5 years. It is through getting rid of the dead space. One waits till late in the process to scale up manufacturing. But for Covid-19, we did seamless phases of trials without any dead space. Manufacturers have scaled up their processes, and it is a reasonable risk to take”.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.